From a therapeutic standpoint, siRNA knock-down of ECT2 in glioblastoma cell lines caused decreased proliferation, migration and invasion [49], and mice with U251 astrocytoma cell line xenografts expressing ECT2 shRNAs showed significantly greater survival than non-targeting shRNA controls [42], making it an interesting target. The gene discussed is ECT2; the disease is astrocytoma (excluding glioblastoma).